American Journal of Hematology

publication venue for

A COMPARATIVE STUDY OF DIFFERENT METHODS OF HANDLING MISSING DATA IN PATIENT REPORTED OUTCOMES, BURDENS AND EXPERIENCES (PROBE) SCORE ALGORITHM AMONG PEOPLE WITH HEMOPHILIA 2023
ANTIBODIES IN HITT AND VITT 2023
ANTICOAGULATION OF MECHANICAL HEART VALVES IN PREGNANCY 2023
COLLABORATION FOR THE LONG-TERM FOLLOW-UP OF PEOPLE WITH HEMOPHILIA TREATED WITH GENE THERAPY: WORLD FEDERATION OF HEMOPHILIA- AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK 2023
EVIDENCE OF ENDOTHELIAL ACTIVATION INDUCED BY LEUKEMIC BLASTS IN A COCULTURE SYSTEM 2023
MULTICENTER RANDOMIZED TRIAL EVALUATING ILIAC VEIN STENT PLACEMENT IN PATIENTS WITH POST-THROMBOTIC SYNDROME AFTER DEEP VEIN THROMBOSIS 2023
NATIONAL ECONOMIC BURDEN OF ADULTS WITH SEVERE HEMOPHILIA A MANAGED WITH PROPHYLAXIS IN THE UNITED STATES 2023
NEUROCOGNITIVE AND NEUROLOGICAL OUTCOMES IN CHILDREN WITH HEMOPHILIA B ARE UNAFFECTED BY LONG-TERM EXPOSURE TO NONACOG BETA PEGOL (N9-GP) 2023
PATHOGENESIS OF PLATELET PROTHROMBOTIC STATES (HITT/VITT) 2023
DOES WARFARIN REALLY CAUSE ACUTE KIDNEY INJURY? A RETROSPECTIVE STUDY 2018
EVALUATION OF RELATIONSHIPS BETWEEN PLATELET DENSE GRANULE DEFICIENCY, IMPAIRED AGGREGATION RESPONSES, AND IMPAIRED DENSE GRANULE ADENOSINE TRIPHOSPHATE RELEASE 2018
FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, IS ACTIVE IN THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: RESULTS OF THE SOAR PHASE 2, MULTICENTER, OPEN-LABEL STUDY 2018
IMPROVING LABORATORY TESTING FOR HEPARIN INDUCED THROMBOCYTOPENIA 2018
ORAL ANTICOAGULANT DOSING, ADMINISTRATION, AND STORAGE: A CROSS-SECTIONALSURVEYOF CANADIAN HEALTH CARE PROVIDERS 2018
ANDEXANET ALFA, A UNIVERSAL ANTIDOTE FOR REVERSAL OF ANTICOAGULATION OF FACTOR XA INHIBITORS IN HEALTHY HUMAN VOLUNTEERS 2016
ATTENUATING FIBRINOLYSIS INCREASES THROMBUS STABILITY AND DECREASES PULMONARY EMBOLISM BURDEN 2016
CLINICAL CHARACTERISTICS AND OUTCOMES OF 'EARLY SWITCHERS': A SUBSET OF PATIENTS FROM XALIA, A PROSPECTIVE NON-INTERVENTIONAL STUDY 2016
EFFECTS OF FONDAPARINUX AND RIVAROXABAN ON CLOT FORMATION IN FACTOR VIII-DEFICIENT, BUT VON WILLEBRAND FACTOR-SUPPLEMENTED, PLASMA MIMICKING PLASMA SAMPLES OBTAINED FROM HEMOPHILIA A PATIENTS 2016
NHF-MCMASTER GUIDELINE ON CARE MODELS FOR HEMOPHILIA MANAGEMENT 2016
P-SELECTIN-BINDING, PROCOAGULANT MICROPARTICLES DO NOT PREDICT RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A PREVIOUS UNPROVOKED EVENT 2016
PREDICTORS OF MAJOR BLEEDING DURING WARFARIN INTERRUPTION FOR INVASIVE PROCEDURES: ANALYSIS OF THE BRIDGE TRIAL 2016
AN IN VITROMODEL USING THROMBOELASTOGRAPHY TO EXAMINE THE EFFECTS OF HEPARIN ON CLOT FORMATION IN PLATELET-DEPLETED WHOLE BLOOD 2014
CLINICAL UTILITY OF 1:1 ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) MIXING STUDY USING A LUPUS INSENSITIVE REAGENT. 2014
MULTIMERIN1 BINDS TO A CONSENSUS SEQUENCE ON COLLAGEN THAT SUPPORTS PLATELET ADHESION 2014
PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH INHIBITORS TO ADAMTS13 RESPONDED SLOWER TO PLASMA EXCHANGE THAN THOSE WITHOUT INHIBITOR: A SYSTEMATIC REVIEW OF THE LITERATURE 2014
RIVAROXABAN FOR THROMBOPROPHYLAXIS AFTER NON-ELECTIVE ORTHOPAEDIC SURGERY IN ROUTINE CLINICAL PRACTICE 2014
RIVAROXABAN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT SURGERY: COMPARISON OF OUTCOMES OF THE XAMOS AND RECORD STUDIES 2014
USE OF EXTENDED HALF-LIFE FACTOR IX PRODUCTS IN REPRESENTATIVE PAEDIATRIC PATIENTS WITH SEVERE FACTOR IX DEFICIENCY 2014
VARIABILITY IN FINDINGS FOR PLATELET DENSE GRANULE ADENOSINE TRIPHOSPHATE RELEASE AMONGST PATIENTS WITH MULTIPLE EVALUATIONS: IMPLICATIONS FOR DIAGNOSIS 2014
VWF A1A2A3 DOMAINS SUPPORT MMRN1 PLATELET ADHESIVE PROPERTIES 2014
An In Vitro Model to Study the Effect of Anticoagulants On Clot Formation in Platelet-Enriched Plasma 2012
Are Clinical Laboratories Following Published Guidelines for the Interpretation of Light Transmission Aggregometry? Results from a Nascola Patterns-of-Practice Survey 2012
Bleeding Risk in Randomized Controlled Trials Comparing Warfarin and Aspirin: A Systematic Review and Meta-Analysis 2012
Can Low-Molecular-Weight Heparin Be Safely Used as Prophylaxis Against Venous Thromboembolism in Critically Ill Patients with End-Stage Renal Disease? A Subgroup Analysis of the Protect Trial 2012
Death and Thrombosis After Interrupting Warfarin for Gastrointestinal Hemorrhage 2012
Rofecoxib Does Not Appear to Increase the Risk of Venous Thromboembolism: A Systematic Review of the Available Literature 2012
Use of Thrombolytic Agents for Pulmonary Embolism During Cardiopulmonary Resuscitation: Systematic Review and Teleoanalysis 2012
AN APPROACH FOR THE DEVELOPMENT OF REFERENCE INTERVALS FOR PLATELET AGGREGATION TESTING 2008
ARE CLINICAL LABORATORIES FOLLOWING ISTH RECOMMENDATIONS FOR LUPUS ANTICOAGULANT TESTING? RESULTS OF A 2(ND) NASCOLA SURVEY 2008
EVALUATION OF PLATELET AGGREGATION RESPONSES IN SAMPLES WITH REDUCED PLATELET COUNTS 2008
NASCOLA 1997-2007: LOOKING BACK AND FORWARD 2008
PLATELET FUNCTIONAL DISORDERS AND TESTING 2008
THE EFFECT OF DIFFERENT SAMPLE TYPES ON COAGULATION LABORATORY TESTS 2008
THE NASCOLA/ECAT LUPUS ANTICOAGULANT (LA) AND ANTIPHOSPHOLIPID ANTIBODY (APL) TESTING PRACTICES QUESTIONNAIRE 2008
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).. 99:2084-2095. 2024
Quadruplets in newly diagnosed transplant-ineligible multiple myeloma.. 99:2249-2252. 2024
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes. 99:2063-2074. 2024
Still high risk? A review of translocation t(14;16) in multiple myeloma. 99:1979-1987. 2024
Bleeding self‐assessments by patients with immune thrombocytopenia (ITP): An agreement study. 99:1184-1186. 2024
Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia. 99:615-624. 2024
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies. 99:473-476. 2024
Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP‐C. 99:274-283. 2024
The complex relationship between iron status and anemia in pregnant and postpartum women in India: Analysis of two Indian study cohorts of uncomplicated pregnancies. 98:1721-1731. 2023
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study. 98:E197-E199. 2023
Perioperative management of myeloproliferative neoplasms: A pan‐Canadian physician survey and international expert opinion. 97:E466-E469. 2022
Understanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences, and beyond. 97:1659-1663. 2022
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study. 97:691-699. 2022
Acute thrombocytopenia suggesting thrombotic microangiopathy. 97:659-665. 2022
Clinical phenotypes of three children with sickle cell disease caused by HbS/Sicilian (δβ)⁰‐thalassemia deletion. 97:E156-E158. 2022
Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP‐C. 96:796-804. 2021
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination. 96:534-537. 2021
Serotonin‐release assay‐positive but platelet factor 4‐dependent enzyme‐immunoassay negative: HIT or not HIT?. 96:320-329. 2021
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life. 96:199-207. 2021
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. 96:188-198. 2021
Characterization of the severe phenotype of pyruvate kinase deficiency. 95:E281-E285. 2020
Limitations of the particle immunofiltration assay test for diagnosis of heparin‐induced thrombocytopenia. 95:E250-E254. 2020
Venous limb gangrene and pulseless electrical activity (PEA) cardiac arrest during management of deep‐vein thrombosis and progressive limb ischemic necrosis following vascular surgery. 95:712-717. 2020
Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. 95:472-482. 2020
Serotonin‐release assay‐negative heparin‐induced thrombocytopenia. 95:38-47. 2020
Second‐line treatments in children with immune thrombocytopenia: Effect on platelet count and patient‐centered outcomes. 94:741-750. 2019
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. 94:697-709. 2019
How we diagnose and manage altered oxygen affinity hemoglobin variants. 94:597-603. 2019
Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. 94:546-553. 2019
Utility and prognostic value of ¹⁸F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma. 93:1518-1523. 2018
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials. 93:921-930. 2018
Physician decision making in selection of second‐line treatments in immune thrombocytopenia in children. 93:882-888. 2018
The risk of venous thromboembolism in patients with clinically overt gastrointestinal bleeding. 93:E42-E45. 2018
ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems. 92:1037-1046. 2017
Sepsis and persisting neutropenia in a drug addict. 92:312-316. 2017
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.. 92:77-81. 2017
A candidate transacting modulator of fetal hemoglobin gene expression in the Arab—Indian haplotype of sickle cell anemia. 91:1118-1122. 2016
Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. 91:E327-E329. 2016
Homozygosity for a haplotype in the HBG2‐OR51B4 region is exclusive to Arab‐Indian haplotype sickle cell anemia. 91:E308-E311. 2016
Long‐term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. 91:623-630. 2016
Non–injection‐site necrotic skin lesions complicating postoperative heparin thromboprophylaxis. 90:747-750. 2015
Pitfalls in the diagnosis of heparin‐Induced thrombocytopenia: A 6‐year experience from a reference laboratory. 90:629-633. 2015
The platelet serotonin‐release assay. 90:564-572. 2015
Risk infection to spare bleeding? The quandary of splenectomy for immune thrombocytopenia. 90:271-272. 2015
The genetics of hemoglobin A₂ regulation in sickle cell anemia. 89:1019-1023. 2014
Haptoglobin testing in hemolysis: Measurement and interpretation. 89:443-447. 2014
Sweet's syndrome in chronic myelomonocytic leukemia. 88:630-630. 2013
Genetic studies of fetal hemoglobin in the Arab‐Indian haplotype sickle cell‐β⁰ thalassemia. 88:531-532. 2013
Platelet count or bleeding as the outcome in ITP trials?. 87:945-946. 2012
Immune thrombocytopenia: Getting back to basics. 87:841-842. 2012
A functional promoter polymorphism of the δ‐globin gene is a specific marker of the Arab‐Indian haplotype. 87:824-826. 2012
Erratum. 87:748-748. 2012
Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. 87:S100-S107. 2012
Approaches to investigating common bleeding disorders: An evaluation of North American coagulation laboratory practices. 87:S45-S50. 2012
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. 87:S141-S145. 2012
HITlights: A career perspective on heparin‐induced thrombocytopenia. 87:S92-S99. 2012
New oral anticoagulants: A view from the laboratory. 87:S133-S136. 2012
Fetal hemoglobin in sickle cell anemia: Molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. 87:217-219. 2012
Is HbA₂ level a reliable diagnostic measurement for β‐thalassemia trait in people with iron deficiency?. 87:114-116. 2012
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study. 86:914-917. 2011
Erratum to: Unexpectedly low pulse oximetry measurements associated with variant hemoglobins: A systematic review. 86:722-725. 2011
Chills and limb pain following administration of low‐molecular‐weight heparin for treatment of acute venous thromboembolism. 86:603-606. 2011
Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. 86:612-614. 2011
Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit “overdiagnosis” in a patient with antiphospholipid syndrome. 86:188-191. 2011
Hepcidin in anemia of chronic heart failure. 86:107-109. 2011
Unexpectedly low pulse oximetry measurements associated with variant hemoglobins: A systematic review. 85:882-885. 2010
Coagulopathy in a patient with nephrotic syndrome. 85:708-710. 2010
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. 84:579-583. 2009
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. 84:584-588. 2009
Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients. 84:603-606. 2009
Novel 27.9 kb α⁰‐thalassemia deletion in a Filipino woman. 84:197-198. 2009
Hemoglobin Kenya composed of α‐ and (^Aγβ)‐fusion‐globin chains, associated with hereditary persistence of fetal hemoglobin. 84:55-58. 2009
Laboratory testing for fibrinogen abnormalities. 83:928-931. 2008
Delayed‐onset HIT caused by low‐molecular‐weight heparin manifesting during fondaparinux prophylaxis. 83:876-878. 2008
Variation and heritability of Hb F and F‐cells among β‐thalassemia heterozygotes in Hong Kong. 83:458-464. 2008
What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?. 82:1037-1043. 2007
Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected with Staphylococcus epidermidis: Role of monocyte procoagulant activity induced by bacterial supernatant. 82:766-771. 2007
Hemoglobin SE disease—A concise review. 82:643-649. 2007
Chronic eosinophilic leukemia presenting with autoimmune hemolytic anemia and erythrophagocytosis by eosinophils. 81:458-461. 2006
Hemoglobinopathies mimicking Hb S/β‐thalassemia: Hb S/S with α‐thalassemia and Hb S/Volga. 81:361-365. 2006
Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. 78:188-192. 2005
Dissociation between the level of von Willebrand factor‐cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. 77:387-390. 2004
Hemoglobin Titusville, a low oxygen affinity variant hemoglobin, in a family of Northern European background. 77:384-386. 2004
Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies. 76:373-377. 2004
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. 76:205-213. 2004
Erratum. 76:99-99. 2004
Warfarin‐associated multiple digital necrosis complicating heparin‐induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma‐associated thrombotic endocarditis. 75:56-62. 2004
β‐thalassemia in association with a new δ‐chain hemoglobin variant [δ116(g18)Arg→Leu]: Implications for carrier screening and prenatal diagnosis. 74:179-181. 2003
Health status and health‐related quality of life associated with von Willebrand disease. 73:108-114. 2003
Health status and health‐related quality of life associated with hemophilia. 71:152-160. 2002
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin‐induced thrombocytopenia. 71:50-52. 2002
Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). 69:192-199. 2002
Hemoglobin H (Hb H) disease in Canada: Molecular diagnosis and review of 116 cases. 68:11-15. 2001
CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. 67:34-41. 2001
Platelet factor V New York: A defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. 66:130-139. 2001
β‐thalassemia intermedia caused by compound heterozygosity for Hb Malay (β codon 19 AAC→AGC; Asn→Ser) and codons 41/42 (‐CTTT) β ⁰ ‐thalassemia mutation. 64:206-209. 2000
PCR-based diagnosis of the Filipino (??FIL) and Thai (??THAI) ?-thalassemia-1 deletions. 63:54-56. 2000
Radiotherapy to control CNS lymphomatoid granulomatosis: A case report and review of the literature. 62:239-241. 1999
Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. 62:44-48. 1999
A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia. 60:126-129. 1999
Low-molecular-weight Heparin for the treatment of venous thrombosis in patients with adenocarcinoma. 59:260-261. 1998
Platelet activation induced by porcine factor VIII (HYATE:C). 57:200-205. 1998
De novo mutation of the β-globin gene initiation codon (ATG→AAG) in a Northern European. 56:179-182. 1997
Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants. 56:131-142. 1997
Differences between platelet phosphoinositide metabolism stimulated by thrombin or SFLLRN are not accounted for by interaction of thrombin with glycoprotein Ib. 54:288-295. 1997
Failure of pulse high‐dose dexamethasone in chronic idiopathic immune thrombocytopenia. 54:267-270. 1997
Acute hemolytic anemia precipitated by myocardial infarction and pericardial tamponade in G6PD deficiency. 51:174-175. 1996
CD2+, CD3‐, CD56/NCAM+ malignant lymphoma with TCRβ gene rearrangement: A case report. 50:209-214. 1995
Severity of β‐thalassemia due to genotypes involving the IVS‐I‐6 (T→C) mutation. 50:15-19. 1995
Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia. 48:221-227. 1995
INR reporting in Canadian medical laboratories. 48:237-239. 1995
INR reporting in Canadian medical laboratories. Thrombosis Interest Group of Canada.. 48:237-239. 1995
Response to “treatment of childhood chronic ITP”. 48:210-210. 1995
Profound thrombocytopenia complicating dietary erucic acid therapy for adrenoleukodystrophy. 48:132-133. 1995
Hb E/Hb Lepore_Hollandia in a family from Bangladesh. 47:262-265. 1994
DNA diagnosis of Hb S and Hb Caribbean (α₂β₂⁹¹ Leu→Arg) in a Jamaican family. 47:33-35. 1994
Genetic linkage studies in antithrombin‐deficient kindreds using a highly polymorphic trinucleotide short tandem repeat (str) within the human antithrombin gene. 46:107-111. 1994
Stability of factor VIII concentrates after reconstitution. 45:217-223. 1994
Detection of the (–^SEA) double α‐globin gene deletion by a simple immunologic assay for embryonic ζ‐globin chains. 44:22-28. 1993
Clinical course and molecular characterization of a compound heterozygote for sickle hemoglobin and hemoglobin kenya. 41:289-291. 1992
Hb S/β°‐Thalassemia due to the ˜1.4‐kb deletion is associated with a relatively mild phenotype. 38:108-112. 1991
Amegakaryocytic thrombocytopenia of 4 years duration: Successful treatment with antithymocyte globulin. 37:126-127. 1991
A new frameshift β°‐thalassemia mutation (codons 27–28 +C) found in a Chinese family. 37:6-8. 1991
Antithrombin III‐Amiens: A new family with an Arg⁴⁷ → cys inherited variant of antithrombin iii with impaired heparin cofactor activity. 36:25-29. 1991
Evaluation of an automated bleeding time device in the newborn. 35:275-277. 1990
Alloimmune neonatal thrombocytopenia associated with incidental maternal thrombocytopenia. 35:43-44. 1990
Acetylcholinesterase in the human erythron. III. Regulation of differentiation. 34:259-261. 1990
Orthotopic liver transplantation in a patient with combined hemophilia A and B. 33:136-138. 1990
Splenic cyst carcinoma presenting in pregnancy. 32:57-60. 1989
Positional effect of cis/trans alpha globin gene deletions on the formation of “H” bodies. 31:242-247. 1989
Modified bleeding time in the infant. 30:190-191. 1989
Biochemical assays of hemoglobin in normal human erythroid clones. 30:27-31. 1989
Acetylcholinesterase in the human erythron. I. Cytochemistry. 28:252-259. 1988
Acetylcholinesterase in the human erythron. II. Biochemical assay. 28:260-265. 1988
Neonatal alloimmune thrombocytopenia: Spontaneous in utero intracranial hemorrhage. 28:98-102. 1988
Prognostic implications of basophil differentiation in chronic myeloid leukemia. 27:110-114. 1988
Carrier detection in the hemophilias. 26:285-296. 1987
Acetylcholinesterase in red blood cells. 26:101-112. 1987
Platelet IgG Fc receptor. 25:299-310. 1987
High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study. 23:131-134. 1986
Treatment of patients with acute nonlymphocytic leukemia in relapse: A leukemia intergroup study. 19:167-176. 1985
Comparison of the measurement of surface or total platelet‐associated IgG in the diagnosis of immune thrombocytopenia. 18:1-5. 1985
Hemoglobin Hamilton or α₂β₂11(a8)Val→Ile: A silent β‐chain variant detected by triton X‐100 acid‐urea polyacrylamide gel electrophoresis. 16:47-52. 1984
The treatment of acute myelocytic leukemia in patients 30 years of age and younger. 13:189-198. 1982
Tumours of the mononuclear phagocyte system: A review of clinical and pathological features. 13:171-184. 1982
Hemoglobin E diseases: Hematological, analytical, and biosynthetic studies in homozygotes and double heterozygotes for α‐thalassemia. 13:15-21. 1982
The role of autologous helper and suppressor T cells in the regulation of human granulopoiesis. 12:323-326. 1982
Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: Direct measurement of percent release of β-thromboglobulin and assessment by flow cytometry of P-selectin expression \textbar Request PDF 1996

American Journal of Hematology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)